Jennifer M. Yeh, PhD; Anju Nohria, MD; Lisa Diller, MD
Grant Support: Dr. Yeh was supported by the National Cancer Institute (grant K07-CA143044).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2266.
Reproducible Research Statement: Study protocol: Available from Dr. Yeh (e-mail, email@example.com). Statistical code and data set: Not available.
Requests for Single Reprints: Jennifer M. Yeh, PhD, Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Yeh: Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115.
Dr. Nohria: Brigham and Women's Hospital/Dana-Farber Cancer Institute, 75 Francis Street, Boston, MA 02115.
Dr. Diller: Dana-Farber Cancer Institute/Boston Children's Hospital, 44 Binney Street, Boston, MA 02115.
Author Contributions: Conception and design: J.M. Yeh, A. Nohria, L. Diller.
Analysis and interpretation of the data: J.M. Yeh, A. Nohria, L. Diller.
Drafting of the article: J.M. Yeh, A. Nohria, L. Diller.
Critical revision of the article for important intellectual content: J.M. Yeh, A. Nohria, L. Diller.
Final approval of the article: J.M. Yeh, A. Nohria, L. Diller.
Statistical expertise: J.M. Yeh.
Obtaining of funding: L. Diller.
Administrative, technical, or logistic support: L. Diller.
Collection and assembly of data: J.M. Yeh.
Childhood cancer survivors treated with cardiotoxic therapies are recommended to have routine cardiac assessment every 1 to 5 years, but the long-term benefits are uncertain.
To estimate the cost-effectiveness of routine cardiac assessment to detect asymptomatic left ventricular dysfunction and of angiotensin-converting enzyme inhibitor and β-blocker treatment to reduce congestive heart failure (CHF) incidence in childhood cancer survivors.
Literature, including data from the Childhood Cancer Survivor Study.
Childhood cancer survivors.
Interval-based echocardiography assessment every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or β-blocker treatment for patients with positive test results.
Lifetime risk for systolic CHF, lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios (ICERs).
The lifetime risk for systolic CHF among 5-year childhood cancer survivors aged 15 years was 18.8% without routine cardiac assessment (average age at onset, 58.8 years). Routine echocardiography reduced lifetime risk for CHF by 2.3% (with assessment every 10 years) to 8.7% (annual assessment). The ICER for assessment every 10 years was $111 600 per quality-adjusted life-year (QALY) compared with no assessment. Assessment every 5 years had an ICER of $117 900 per QALY, and ICERs for more frequent assessment exceeded $165 000 per QALY.
Results were sensitive to treatment effectiveness, absolute excess risk for CHF, and asymptomatic left ventricular dysfunction asymptomatic period. The probability that assessment every 10 or 5 years was preferred at a $100 000-per-QALY threshold was 0.33 for the overall cohort.
Treatment effectiveness was based on adult data.
Current recommendations for cardiac assessment may reduce CHF incidence, but less frequent assessment may be preferable.
National Cancer Institute.
Yeh JM, Nohria A, Diller L. Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction in Childhood Cancer Survivors: A Model-Based Estimation of the Clinical and Economic Effects. Ann Intern Med. 2014;160:661–671. doi: 10.7326/M13-2266
Download citation file:
Published: Ann Intern Med. 2014;160(10):661-671.
Cancer Survivorship, Cardiac Diagnosis and Imaging, Cardiology, Heart Failure, Hematology/Oncology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use